Home › Funds › Bellevue Group AG › BSX
Bellevue Group AG position in BSX
BOSTON SCIENTIFIC CORP · Health Care
Bellevue Group AG reported holding 887,650 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$37.9M, representing 0.80% of its reported portfolio and ranking #35 among its reported holdings. Bellevue Group AG has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's BSX position evolved
Bellevue Group AG first disclosed a stake in BSX in Q3 2023 at 2,646,295 shares (US$139.7M). The position peaked in Q1 2024 at 3,148,676 shares, worth US$215.7M. Across 12 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 10 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 887,650 shares valued at US$37.9M — a reduction of -579,244 shares quarter over quarter.. Notable position changes include a 39% trim in Q2 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.65M | $139.72M | New |
| Q4 2023 | 3.17M | $183.29M | Add |
| Q1 2024 | 3.15M | $215.65M | Reduce |
| Q2 2024 | 2.57M | $197.88M | Reduce |
| Q3 2024 | 2.45M | $205.54M | Reduce |
| Q4 2024 | 2.14M | $190.72M | Reduce |
| Q1 2025 | 1.95M | $196.82M | Reduce |
| Q2 2025 | 1.77M | $189.60M | Reduce |
| Q3 2025 | 1.66M | $162.05M | Reduce |
| Q4 2025 | 1.56M | $148.71M | Reduce |
| Q1 2026 | 1.47M | $92.05M | Reduce |
| Q2 2026 | 887.65K | $37.88M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- Banque Cantonale Vaudoise 67.61K sh · $2.89B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 50.52M sh · $2.16B · Q2 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Arrowstreet Capital 23.29M sh · $994.18M · Q2 2026
- Bollard Group LLC 18.42M sh · $786.20M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held BSX?
Bellevue Group AG has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in BSX?
As of Q2 2026, Bellevue Group AG holds 887.65K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $37.88M, representing 0.80% of its reported portfolio and ranking #35.
Has Bellevue Group AG been buying or selling BSX?
In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in BSX. The position peaked in Q1 2024 at 3.15M shares.
Which other funds hold BSX?
Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.